好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Validation of the Spanish Version of the 15-Item Myasthenia Gravis Quality of Life Scale (MG-QOL15)
Neuromuscular and Clinical Neurophysiology (EMG)
P4 - Poster Session 4 (5:30 PM-6:30 PM)
1-006
Given the fluctuating nature of Myasthenia Gravis(MG), patient-derived measures of quality of life(QOL) are essential in determining disease status in MG. The 15-item MG quality of life scale revised(MG-QOL15r) is validated in English. No disease specific QOL measure exists for Spanish-speaking MG patients. We aim to present preliminary data of a Spanish version of the MG-QOL15 and investigate its reliability and validity for Spanish speaking patients.
N/A

Our team followed a published linguistic guideline in translating the Spanish version of MG-QOL15 form(MG-QOL15S). Patients with MG are recruited at their scheduled clinic visit.  The MG-QOL15S and the Spanish version of the SF-36 form are completed by the patient prior to see the neurologist.  Patients repeat the MG-QOL15S survey 2 days later. Our primary end point is to determine the Internal consistency of the MG-QOL15S. Our secondary endpoints include examining the test-retest reliability and validity of the scale and assessing construct validity between the MG-QOL15S and the Myasthenia Gravis specific Manual Muscle test(MG-MMT) and the Myasthenia Gravis-Activities of Daily living scale(MG-ADL).
Initial data includes 18 patients from Harbor-UCLA Medical Center. The Cronbach Alpha Score was very high(0.91), indicating that the internal consistency of the MG-QOL15S is comparable to the MG-QOL15r. The intra-class correlation coefficient(ICC) was also very high(0.91. 95% CI: 0.76, 0.96), indicating a good test-retest reliability. While there is only moderate correlation between the MG-QOL15S and the MG-MMT(r=0.7) and MG-ADL scales(r=0.6), this is on par with correlation between the MG-MMT and the MG-ADL scales(r=0.6).
At Harbor UCLA Medical Center, we have recently translated the MG-QOL15 into Spanish and demonstrated that even with a small sample size, the data suggests that the MG-QOL15S is valid and reliable. We aim to expand our recruitment efforts to 2 additional neuromuscular clinics as well as compare to another established QOL scale, the 36-item Short Form(SF-36).
Authors/Disclosures
Marcus Cimino, MD (University of Pennsylvania)
PRESENTER 		No disclosure on file
Margaret Adler, MD (Harbor UCLA Department of Neurology) Dr. Adler has nothing to disclose.
Bhavesh Trikamji, MD (University of California Los Angeles) Dr. Trikamji has nothing to disclose.
Namita Goyal, MD, FAAN (University of California, Irvine) Dr. Goyal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Goyal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Annexon. Dr. Goyal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Goyal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Goyal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Souffle. Dr. Goyal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for CSL Behring. Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Argenx. Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amgen. The institution of Dr. Goyal has received research support from Fulcrum. The institution of Dr. Goyal has received research support from Healey Platform. The institution of Dr. Goyal has received research support from Medicinova. The institution of Dr. Goyal has received research support from Transposon. The institution of Dr. Goyal has received research support from Abcuro. The institution of Dr. Goyal has received research support from Calico. The institution of Dr. Goyal has received research support from Clene. The institution of Dr. Goyal has received research support from Janssen. The institution of Dr. Goyal has received research support from PepGen. The institution of Dr. Goyal has received research support from PTC. The institution of Dr. Goyal has received research support from Roche. The institution of Dr. Goyal has received research support from Sanofi. The institution of Dr. Goyal has received research support from Prilenia. The institution of Dr. Goyal has received research support from RAPA. The institution of Dr. Goyal has received research support from Avidity. Dr. Goyal has received publishing royalties from a publication relating to health care.
Frank Lin, MD No disclosure on file
Luis A. Chui, MD No disclosure on file